Chardan Capital Reaffirms “Buy” Rating for Gain Therapeutics (NASDAQ:GANX)

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reissued by research analysts at Chardan Capital in a research report issued on Friday,Benzinga reports. They presently have a $6.00 price target on the stock. Chardan Capital’s target price would indicate a potential upside of 189.86% from the company’s current price.

Other analysts also recently issued research reports about the stock. Scotiabank started coverage on shares of Gain Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price target on the stock. Roth Mkm reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, December 24th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Monday, March 17th. Finally, Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $8.20.

Gain Therapeutics Trading Down 1.0 %

Shares of Gain Therapeutics stock opened at $2.07 on Friday. The firm has a market cap of $54.91 million, a price-to-earnings ratio of -1.88 and a beta of 0.14. Gain Therapeutics has a 52-week low of $0.89 and a 52-week high of $4.04. The company’s 50-day simple moving average is $2.23 and its 200-day simple moving average is $2.05. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.07. As a group, equities research analysts anticipate that Gain Therapeutics will post -1 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC grew its stake in shares of Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after buying an additional 88,236 shares in the last quarter. Jones Financial Companies Lllp grew its position in Gain Therapeutics by 83.6% in the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after acquiring an additional 44,750 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Gain Therapeutics during the fourth quarter valued at approximately $198,000. Northern Trust Corp raised its stake in shares of Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after purchasing an additional 39,642 shares during the period. Finally, Bridgeway Capital Management LLC acquired a new position in shares of Gain Therapeutics during the fourth quarter worth $65,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.